The company's Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 16% to Rs. 190 crores as compared to Rs. 164 crores. 

The company's domestic Business records highest ever sales in a quarter of Rs. 418 crore registering growth of 34%. 

JB Pharma, one of the fastest growing pharmaceutical companies in India, announced its financial results for the first quarter ended 30th June 2022.

For the first quarter ended 30th June 2022, the Company recorded revenue of Rs. 785 crore as compared to Rs. 606 crores, registering growth of 30% over the corresponding quarter. Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 16% to Rs. 190 crores as compared to Rs. 164 crores. 

Profit after Tax stood at Rs. 105 crores on account of higher treasury income in Q1FY 22.

The company's domestic Business records highest ever sales in a quarter of Rs. 418 crore registering growth of 34%. 

International business recorded robust revenue growth of 28% to INR 366 crores with exports formulations, CMO and API business recorded growth of 11%, 108% and 17% respectively.